UnknownPhase 4

ED50 of Intratecal Prilocaine in Ultrasound Fusion Prostate Biopsy

Spain90 participantsStarted 2022-11-24

Plain-language summary

The aim of the present study was to determine the ED50 and ED90 of intrathecal hyperbaric 2% prilocaine (HP) for patients undergoing ambulatory prostate biopsy via magnetic resonance imaging (MRI)/ultrasound fusion.

Who can participate

Age range18 Years – 85 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: ASA II-III patients Aged 18-85 years Prostate fusion biopsy procedure Scheduled to ambulatory surgery Signed informed consent Exclusion Criteria: * Standard contraindications to neuraxial blockade, coagulopathy, site infection, neurological impairment, known allergy to local anesthetics. Refusal of the patient to participate in the study.

What they're measuring

ED50 of intrathecal hyperbaric 2% prilocaine in transperineal magnetic resonance imaging-transrectal ultrasound fusion guided biopsy

Timeframe: From the baseline, previous to prilocaine adminstration until the end of the prostate biopsy procedure. 30 minutes

Trial details

NCT IDNCT05649020

SponsorHospital General Universitario Gregorio Marañon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

Contact for this trial

Matilde Zaballos, MD, PhD

34657813987 mati@plagaro.net

View on ClinicalTrials.gov More Evaluate Requirements of 2% Prilocaine in MR-UF Prostate Biopsy trials